ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1916

Defining Early-stage Knee Osteoarthritis: A Scoping Review

Jean Liew1, Lauren King2, Armaghan Mahmoudian3, Qiuke Wang4, Tuhina Neogi1 and Gillian Hawker2, 1Boston University School of Medicine, Boston, MA, 2University of Toronto, Toronto, ON, Canada, 3Lund University, Lund, Sweden, 4Erasmus Medical Center, Rotterdam, Netherlands

Meeting: ACR Convergence 2022

Keywords: classification criteria, Osteoarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: Osteoarthritis – Clinical Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Clinical trials of disease-modifying agents in knee osteoarthritis (OA) have largely failed to date. Identifying individuals with knee OA at an earlier stage in the disease process may provide a window of opportunity in which interventions may prove fruitful. However, there is no consensus definition for early-stage knee OA to enable trial enrollment. To better define the construct of early-stage knee OA (EsKOA), we sought to identify how early knee OA has been defined in the literature to date, and the most frequently used elements within the definitions.

Methods: We conducted a scoping literature review using PubMed from database inception to March 18, 2022. We included human studies in which early-stage knee OA was included as a study population or outcome of interest, without language exclusions. Two independent reviewers screened each abstract and full text article. Data were extracted from full text articles and included study characteristics, the EsKOA definition, and the inclusion of demographic, symptoms, standardized patient-reported measures, physical examination, laboratory, imaging, performance-based measures, and gross inspection/histopathologic domains as well as individual elements within the EsKOA definition.

Results: We identified 2289 articles in PubMed, of which 210 were included for data abstraction. Of these, 58 consisted of duplicate cohorts with duplicate definitions of EsKOA and were excluded. Of the remaining 152 articles (32 interventional, 89 observational, 3 qualitative, 24 translational/basic science, 3 solely for criteria development), most were performed in Asia (n=54) or Europe (n=48). All were published after 1990. An EsKOA definition was used as inclusion criterion in 142 studies, for outcome definition in 5, and for development of new criteria in 5.

A detailed definition of EsKOA was lacking in 63 studies. EsKOA was defined by Kellgren-Lawrence (KL) radiographic OA grade alone in 39 (with many including KL grade 2), or by previously developed early OA criteria by Luyten, et al. in 13 studies. Fulfilling the 1986 ACR classification criteria for OA was included in the definition in 19 studies.

Demographic domains were included in the EsKOA definition in 30 studies, with 28 including an age cutoff. Symptomatic domains were included in 73 studies and the most common elements were presence of knee pain (49) and pain duration (25). Exam domains were included in 23 studies, with crepitus (14), joint tenderness (12), bony enlargement (6) as the most common elements. Imaging was included in 130 studies (most common element KL grade), gross inspection/histopathologic in 20 (most common element cartilage abnormalities). Only 8 studies included laboratory values, 13 other patient-reported outcomes, 1 performance-based measures.

Conclusion: Although EsKOA has been studied in the published literature, it remains variably defined. Many definitions included fulfilling 1986 ACR classification criteria or KL grades 2+, which reflects established OA, suggesting a failure to truly capture EsKOA. These findings support the need to develop evidence-supported, validated classification criteria for EsKOA.

Supporting image 1

PRISMA flow diagram of study inclusion.

Supporting image 2

Symptom, exam, and imaging elements included in EsKOA definitions in the studies identified by our scoping review


Disclosures: J. Liew, None; L. King, None; A. Mahmoudian, None; Q. Wang, None; T. Neogi, Novartis, Pfizer/Lilly, Regeneron; G. Hawker, None.

To cite this abstract in AMA style:

Liew J, King L, Mahmoudian A, Wang Q, Neogi T, Hawker G. Defining Early-stage Knee Osteoarthritis: A Scoping Review [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/defining-early-stage-knee-osteoarthritis-a-scoping-review/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/defining-early-stage-knee-osteoarthritis-a-scoping-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology